Kutanöz Malign Melanom

Yıl 2014, , 52 - 59, 01.12.2014

Nilay Duman

https://doi.org/10.5505/aot.2014.27247

Öz

Tüm dünyada insidansı giderek artan kutanöz malign melanom derinin en ölümcül kanseridir. Burada kutanöz malign melanom ele alınmış ve epidemiyolojik özellikleri, risk faktörleri, klinik ve histopatolojik özellikleri, evreleme, tedavi ve takip modaliteleri derlenmiştir. Böylelikle kutanöz malign melanom hastasına klinik yaklaşımda kolaylık oluşturulması amaçlanmıştır.

Anahtar Kelimeler

melanom, risk faktörleri, evreleme, tedavi

Cutaneous Malignant Melanoma

Öz

Cutaneous malignant melanoma, the global incidence of which is increasing continuously, is the most lethal skin cancer. Herein, cutaneous malignant melanoma is evaluated and epidemiological features, risk factors, clinical and histopathological features, staging, treatment and follow-up modalities are reviewed. Thus, helping with clinical management of cutaneous malignant melanoma patient is aimed.

Anahtar Kelimeler

melanoma, risk factors, staging, treatment.

Kaynakça

• Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006;355:51-65
• Eggermont AM, Spatz A, Robert C. Cutaneous melanoma Lancet. 2014;383:816-27
• Bandarchi B, Ma L, Navab R, Seth A, Rasty G. From melanocyte to malignant melanoma. Dermatol Res Pract 2010;2010:583748
• Tronnier M, Semkova K, Wollina U, Tchernev G. Malignant diagnostic and therapeutic approach. Wien Med Wochenschr 2013;163:354-8 aspects,
• Tucker MA. Melanoma epidemiology. Hematol Oncol Clin N Am. 2009;23:383-95
• Riker AI, Zea N, Trinh T. The epidemiology, prevention, and detection of melanoma. Ochsner J 2010;10:56-65
• Psaty EL, Scope A, Halpern AC, Marghoob AA. Defining the patient at high risk for melanoma. Int J of Dermatol 2010;49:362-76
• Ingraffea A. Melanoma.Facial Plast Surg Clin North Am 2013;21:33-42
• Palmieri G, Capone M, Ascierto ML, et al. Main roads to melanoma. J Transl Med 2009;7:86-103
• Kong Yunyi, Kumar SM, Xu X. Molecular pathogenesis of sporadic melanoma and melanoma- initiating 2010;134:1740-9 Pathol Lab Med
• Dankort D, Curley DP, Cartlidge RA, et al. Braf (V600E) cooporates with Pten loss to induce metastatic melanoma. Nat Genet 2009;41:544-52
• Patton EE, Widlung HR, Kutok JL, et al. BRAF mutations are sufficient to promote nevi formation and cooporate with p53 in the genesis of melanoma. Curr Biol 2005;15:249-54
• Kraemer KH, Levy DD, Parris CN, et al. Xeroderma pigmentosum and related disorders: examining the linkage between defective DNA repair and cancer. J Invest Dermatol 1994;103:96-101
• Garibyan L, Fisher DE. How sunlight causes melanoma. Curr Oncol Rep. 2010;12:319-26
• The international Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer 2007;120:1116-22
• Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-up Study. N Engl J Med 1997;336:1041-5
• Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44:755-61
• Gandini S, Sera F, Cattaruzza MS, et al. Meta- analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005;41:2040-59
• Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple 294:1647-54 JAMA 2005;
• Hemminki K, Zhang H, Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Invest Dermatol 2003;120:217- 23
• Marghoob AA, Slade J, Salopek TG, Kopf AW, Bart RS, Rigel DS. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant Cancer 1995;75:707-14 implications.
• Pielop JA, Brownell I, Duvic M. Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. Int J Dermatol 2003;42:116-22
• Liu W, Dowling JP, Murray WK, McArthur GA, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol 2006;142:1551-8
• Chamberlain AJ, Fritschi L, Giles GG, Dowling JP, Kelly JW. Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol 2002;138:609-14
• Gandini S, Sera F, Cattaruzza MS, et al. Meta- analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005;41:28-44
• McKenna DB, Stockton D, Brewster DH, Doherty VR. Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland. Br J Cancer 2003;88:74-8
• Brennan P, Coates M, Armstrong B, Colin D, Boffetta P. Second primary neoplasms following non-Hodgkin’s lymphoma in New South Wales, Australia. Br J Cancer 2000;82:1344-7
• Levi F, Randimbison L, Te VC, La Vecchia C. Non- Hodgkin’s leukemias and skin cancers. Br J Cancer 1996;74:1847-50 chronic lymphocytic
• Jensen P, Hansen S, Mİller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosupressive therapy regimens. J Am Acad Dermatol 1999;40:177-86
• Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681- 91
• Yuvale FO, Halpern AC. Melanoma. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology (2nd ed). Spain; Mosby Elsevier;2008:1745-69
• McKee PH, Calonje E. Melanocytic Pathology (3rd ed). China;Mosby Elsevier; 2009
• Elder DE, Elenitsas R, Murphy GF. Benign pigmented lesions and malignant melanoma. In: Elder DE, Elenitsas R, Johnson BL, Murphy GF, Xu X, eds. Histopathology of the skin (10th ed). Philadelphia; Wilkins;2009:699-789 Williams &
• Frishberg DP, Balch C, Balzer BL, et al. Protocol for the examination of specimens from patients with melanoma of the skin. Arch Pathol Lab Med 2009;133:1560-7
• Schuchter L, Schultz DJ, Synyuvavedt M, et al. Aprognostic model for predicting 10-year survival in patients with primary melanoma. Ann Intern Med 1996;125:369-75
• Mangas C, Paradelo C, Puig S, et al. Initial evaluation, diagnosis, staging, treatment, and follow-up of patients with primary cutaneous malignant melanoma. Consensus statement of the Network of Catalan and Balearic Melanoma Centers. Actas Dermosifiliogr 2010;101:129-42
• Maubec E, Lumbroso J, Mason F, et al. F-18 fluorodeoxy-D-glucose tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res 2007;17:147-54 emission
• Brady MS, Akhurst T, Spanknebel K, et al. Utility of preoperative 18F-fluorodeoxyglucose-positron emission melanoma patients. Ann Surg Oncol 2006;13:525-32 in high-risk
• Prichard RS, Hill AD, Skehan SJ, O'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002;89:389-96
• Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G; ESMO Guidelines Working Group. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol 2012;23:vii86-vii91